Fangchinoline inhibits the proliferation of SPC-A-1 lung cancer cells by blocking cell cycle progression
- Authors:
- Published online on: December 4, 2015 https://doi.org/10.3892/etm.2015.2915
- Pages: 613-618
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Fangchinoline (Fan) is a bioactive compound isolated from the Chinese herb Stephania tetrandra S. Moore (Fen Fang Ji). The aim of the present study was to investigate the effect of Fan on the proliferation of SPC‑A‑1 lung cancer cells, and to define the associated molecular mechanisms. Following treatment with Fan, Cell Counting Kit‑8, phase contrast imaging and Giemsa staining assays were used to detect cell viability; flow cytometry was performed to analyze the cell cycle distribution; and reverse transcription‑quantitative polymerase chain reaction and western blot assays were used to investigate changes in the expression levels of cell cycle‑associated genes and proteins. In the present study, treatment with Fan markedly inhibited the proliferation of SPC‑A‑1 lung cancer cells and significantly increased the percentage of cells in the G0/G1 phase of the cell cycle in a dose‑dependent manner (P<0.05 for 2.5-5 µm; P<0.01 for 10 µm), whereas the percentage of cells in the S and G2/M phases were significantly reduced following treatment (P<0.05 for 5 µm; P<0.01 for 10 µm). Mechanistically, Fan significantly reduced the mRNA expression levels of cyclin D1, cyclin‑dependent kinase 4 (CDK4) and CDK6 (P<0.05 for 2.5-5 µm; P<0.01 for 10 µm), which are key genes in the regulation of the G0/G1 phase of the cell cycle. Furthermore, treatment with Fan also decreased the expression of phosphorylated retinoblastoma (Rb) and E2F transcription factor‑1 (E2F‑1) proteins (P<0.05 for 5 µm; P<0.01 for 10 µm). In summary, the present study demonstrated that Fan inhibited the proliferation of SPC‑A‑1 lung cancer cells and induced cell cycle arrest at the G0/G1 phase. These effects may be mediated by the downregulation of cellular CDK4, CDK6 and cyclin D1 levels, thus leading to hypophosphorylation of Rb and subsequent suppression of E2F-1 activity. Therefore, the present results suggest that Fan may be a potential drug candidate for the prevention of lung cancer.
